Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features

Bone

Volumn 48, Issue 5, 2011, Pages 966-971

  Giusti, Andrea ^a   Hamdy, Neveen A T ^a   Dekkers, Olaf M ^a   Ramautar, Sharita R ^a   Dijkstra, Sander ^a   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical femoral fractures; Bisphosphonates; Cortical thickness; Glucocorticoids; Subtrochanteric fractures

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; ATYPICAL FEMUR FRACTURE; BONE RADIOGRAPHY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; THICKNESS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED;

EID: 79954629873     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.12.033     Document Type: Article

References (28)

1. Papapoulos S.E. Bisphosphonates for postmenopausal osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism 2008, 237-241. American Society for Bone and Mineral Research, Washington, DC. 7th ed. C.J. Rosen (Ed.).
2. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19(6):733-759.
3. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86(6):421-435.
4. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010, 47(2):169-180.
5. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39(2):224-231.
6. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22(5):346-350.
7. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010, 362(19):1825-1827.
8. Black D.M., Kelly M.P., Genant H.K., et al. Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362(19):1761-1771.
9. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20(8):1353-1362.
10. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24(6):1095-1102.
11. Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362(19):1848-1849.
12. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95(4):1555-1565.
13. Compston J.E. Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas 2010, 65(1):3-4.
14. AO Foundation. Müller AO Classification of Fractures - Long Bones. http://www.aofoundation.org/wps/portal/!ut/p/c0/04_SB8K8xLLM9MSSzPy8xBz9 CP0os3hng7BARydDRwML1yBXAyMvYz8zEwNPQ4MQU_2CbEdFAKf5GSU!/. Accessed December 2009.
15. Marsh J.L., Slongo T.F., Agel J., et al. Fracture and dislocation classification compendium-2007: Orthopaedic Trauma Association classification, database and outcomes committee. J Orthop Trauma 2007, 21(10 Suppl):S1-S133.
16. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21(3):399-408.
17. Glüer C.C., Cummings S.R., Pressman A., et al. Prediction of hip fractures from pelvic radiographs: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1994, 9(5):671-677.
18. Hedlund R., Lindgren U. Epidemiology of diaphyseal femoral fracture. Acta Orthop Scand 1986, 57(5):423-427.
19. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
20. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol Oxf 2010, 72(2):161-168.
21. Bilezikian J, Klemes A, Silverman S, Cosman F. Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res. 2009;24(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=0367 cfaa-4d0d-47d8-a57a-ff76098839a2.
22. Kumm D.A., Rack C., Rütt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997, 12(5):580-583.
23. Niimi R., Hasegawa M., Sudo A., Uchida A. Unilateral stress fracture of the femoral shaft combined with contralateral insufficiency fracture of the femoral shaft after bilateral total knee arthroplasty. J Orthop Sci 2008, 13(6):572-575.
24. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009, 80(4):413-415.
25. Yang K.H., Park S.Y., Park S.W., et al. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. J Bone Miner Metab. 2010, 28(6):713-718.
26. Bunning R.D., Rentfro R.J., Jelinek J.S. Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R 2010, 2(1):76-80.
27. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
28. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90(3):1897-1899.